Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic

Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are excluded. Successful implementation in public healthcare hinges on accurate estimates of eligibility rates in settings which will be the first to roll...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Anna Rosenberg, Alina Solomon, Alexandre Bonnard, Makrina Daniilidou, Göran Hagman, Anette Hall, Anna Matton, Ulf Öhlund-Wistbacka, Eric Westman, Miia Kivipelto
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-03-01
Schriftenreihe:	The Journal of Prevention of Alzheimer's Disease
Schlagworte:	Alzheimer's disease Anti-amyloid antibody Lecanemab Donanemab Eligibility Real world evidence
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2274580725004170
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!